Compounded GLP-1 vs. labeled products: regulatory difference, dosing risk, and what the FDA position actually says

The regulatory distinction in plain language

Branded GLP-1 products (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved finished drugs with full chemistry, manufacturing, and controls (CMC) review. Compounded GLP-1 preparations are made by 503A pharmacies for individual patient prescriptions or by 503B outsourcing facilities for bulk distribution. They do not undergo the same approval, post-market safety, and labeling apparatus.

The compounding pathway exists for legitimate clinical reasons (drug shortage, individualized dosing, allergen avoidance) but it is not a generic-equivalent pathway. The FDA has noted concerns specifically with unapproved GLP-1 products marketed for weight loss and with the bulk substances allowed in compounded preparations .

The dosing-error pattern is documented

FDA has issued explicit alerts on dosing errors associated with compounded GLP-1 products, particularly when patients self-draw from multi-dose vials with syringes, the units-vs-milligrams distinction is unclear, or the concentration differs from the labeled-product reference . Reports include 5-fold and 10-fold overdoses leading to hospitalization.

• Concentration mismatch: compounded vials may not match the labeled-product mg/mL.
• Units confusion: U-100 syringe markings represent insulin units, not milligrams; users converting from a brand pen can misread.
• Reconstitution variability: powder formulations require correct diluent volume; small errors compound across draws.
• Salt-form variability: some compounded preparations have used a different salt form of the active that does not match the labeled product's PK profile.

What the trial data does and does not transfer

Efficacy claims for branded GLP-1 products come from STEP and SURMOUNT . The compounded versions have not been studied in those trials. Pharmacology that depends on the molecule itself (receptor binding, half-life inherent to the molecular structure) plausibly transfers. Pharmacology that depends on formulation (excipients, stability, fill volume, particle size) does not necessarily transfer, and the FDA's CMC review is the only routine check on those factors for the labeled product.

Shortage resolution context

FDA shortage status for branded GLP-1 products has shifted across 2024 and 2025. When a drug is no longer on the FDA shortage list, the regulatory rationale for routine compounding under 503A/503B narrows substantially. Compounded availability and the legal posture both depend on the current shortage list state, which the FDA publishes and updates .